Cargando…
A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
Broadly neutralizing antibodies (bNAbs) are essential for a preventative HIV-1 vaccine but have not been elicited through vaccination. bNAbs develop in 20–30 per cent of HIV-1 infections and often target the V3-glycan epitope of the HIV envelope protein (Env). In these individuals, virus-antibody co...
Autores principales: | Kitchin, D, Bhiman, J, Mvududu, D, Oosthuysen, B, Lambson, B, Madzorera, S, Anthony, C, Abdool Karim, S S, Garrett, N J, Doria-Rose, N A, Mascola, J R, Morris, L, Moore, P L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736059/ http://dx.doi.org/10.1093/ve/vez002 |
Ejemplares similares
-
A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies
por: Mabvakure, B., et al.
Publicado: (2017) -
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies
por: Bhiman, Jinal N., et al.
Publicado: (2015) -
Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022) -
Rapid and Focused Maturation of a VRC01-Class HIV Broadly Neutralizing Antibody Lineage Involves Both Binding and Accommodation of the N276-Glycan
por: Umotoy, Jeffrey, et al.
Publicado: (2019) -
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
por: Cottrell, Christopher A., et al.
Publicado: (2021)